Weighing the pros and cons for composite outcomes in clinical trials

被引：27

作者：

Freemantle, Nick ^{[1
]}

Calvert, Melanie ^{[1
]}

机构：

[1] Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England

来源：

关键词：

D O I：

10.1016/j.jclinepi.2006.10.024

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

引用

页码：658 / 659

页数：2

共 5 条

[1] Some issues with composite endpoints in clinical trials [J].

Chi, GYH .

[2]

FDA Draft Guidance for Industry, 2006, PAT REP OUTC MEAS US

Ferreira-Gonzalez, Ignacio ;

Permanyer-Miralda, Gaieta ;

Busse, Jason W. ;

Bryant, Dianne M. ;

Montori, Victor M. ;

Alonso-Coello, Pablo ;

Walter, Stephen D. ;

Guyatt, Gordon H. .

Freemantle, N ;

Calvert, M ;

Wood, J ;

Eastaugh, J ;

Griffin, C .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (19) :2554-2559

[5]

1999, STAT MED, P1905